ICMJE DISCLOSURE FORM

Date:	Oct. 18 th , 2021		
Your Name:	Brandon Swed		
Manuscript 1	Fitle: ORIENT-32	Trial: Sintilimab +	Bevacizumab Biosimilar as a Promising Combination
Therapy in	Advanced Hepatoco	ellular Carcinoma	
Manuscript i	number (if known):	DMR-21-73	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	xNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	x None	
3	Royalties or licenses	x None	
4	Consulting fees	x None	

5	Payment or honoraria for	x None					
	lectures, presentations,						
	speakers bureaus, manuscript writing or						
	educational events						
6	Payment for expert	x None					
	testimony						
7	Support for attending meetings and/or travel	x None					
8	Patents planned, issued or	x None					
	pending						
9	Participation on a Data	x None					
	Safety Monitoring Board or Advisory Board						
10	Leadership or fiduciary role	x None					
10	in other board, society,	x None					
	committee or advocacy						
	group, paid or unpaid						
11	Stock or stock options	x None					
12	Receipt of equipment,	x None					
	materials, drugs, medical						
	writing, gifts or other services						
13	Other financial or non-	x None					
	financial interests						
Ple	Please summarize the above conflict of interest in the following box:						
ı	None.						

Please place an "X" next to the following statement to indicate your agreement:

__x__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date:	Oct. 18 th , 2021		
Your Name:	Omar Gandarill	<u>a</u>	
Manuscript 1	Title: ORIENT-3	<u> 2 Trial: Sintilimab +</u>	Bevacizumab Biosimilar as a Promising Combination
Therapy in	Advanced Hepato	cellular Carcinoma	
Manuscript i	number (if known): _	DMR-21-73	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	xNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	x None	
3	Royalties or licenses	xNone	
4	Consulting fees	x None	

5	Payment or honoraria for	x None					
	lectures, presentations,						
	speakers bureaus, manuscript writing or						
	educational events						
6	Payment for expert	x None					
	testimony						
7	Support for attending meetings and/or travel	x None					
8	Patents planned, issued or	x None					
	pending						
9	Participation on a Data	x None					
	Safety Monitoring Board or Advisory Board						
10	Leadership or fiduciary role	x None					
10	in other board, society,	x None					
	committee or advocacy						
	group, paid or unpaid						
11	Stock or stock options	x None					
12	Receipt of equipment,	x None					
	materials, drugs, medical						
	writing, gifts or other services						
13	Other financial or non-	x None					
	financial interests						
Ple	Please summarize the above conflict of interest in the following box:						
ı	None.						

Please place an "X" next to the following statement to indicate your agreement:

__x__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date:	<u>Oct. 18^t</u>	th . 2021					
Your Name	e:Gaga	ındeep Brar					
Manuscrip	t Title:	ORIENT-32	Trial: Sintilimab +	Bevacizumab	Biosimilar a	as a Promising	<u>Combination</u>
Therapy i	n Advano	ced Hepatoc	ellular Carcinoma			_	
Manuscrip	t number	(if known):	DMR-21-73				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	xNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	x None	
3	Royalties or licenses	xNone	
4	Consulting fees	x None	

5	Payment or honoraria for	x None					
	lectures, presentations,						
	speakers bureaus, manuscript writing or						
	educational events						
6	Payment for expert	x None					
	testimony						
7	Support for attending meetings and/or travel	x None					
8	Patents planned, issued or	x None					
	pending						
9	Participation on a Data	x None					
	Safety Monitoring Board or Advisory Board						
10	Leadership or fiduciary role	x None					
10	in other board, society,	x None					
	committee or advocacy						
	group, paid or unpaid						
11	Stock or stock options	x None					
12	Receipt of equipment,	x None					
	materials, drugs, medical						
	writing, gifts or other services						
13	Other financial or non-	x None					
	financial interests						
Ple	Please summarize the above conflict of interest in the following box:						
ı	None.						

Please place an "X" next to the following statement to indicate your agreement:

__x__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.